imipenem Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring	1426	64221-86-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: imipenem tienamycin imipemide imipenen imipenem hydrate	Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Molecular weight: 299.35 Formula: C12H17N3O4S CLOGP: -1.35 LIPINSKI: 0 HAC: 7 HDO: 4 TPSA: 113.72 ALOGS: -2.64 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

imipenem
tienamycin
imipemide
imipenen
imipenem hydrate

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Molecular weight: 299.35
Formula: C12H17N3O4S
CLOGP: -1.35
LIPINSKI: 0
HAC: 7
HDO: 4
TPSA: 113.72
ALOGS: -2.64
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	P
2	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	69 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	222.82 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.86 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.95 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
June 23, 2021	PMDA	MSD K.K.
Feb. 13, 2020	EMA	Merck Sharp & Dohme B.V.
Nov. 26, 1985	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Epilepsy	313.54	20.63	129	8873	25638	53314426
Pathogen resistance	180.87	20.63	60	8942	6500	53333564
Septic shock	152.41	20.63	107	8895	62122	53277942
Multiple organ dysfunction syndrome	127.69	20.63	92	8910	55585	53284479
Seizure	108.49	20.63	121	8881	129388	53210676
Drug reaction with eosinophilia and systemic symptoms	108.33	20.63	68	8934	32732	53307332
Sepsis	85.47	20.63	114	8888	146315	53193749
Drug resistance	77.72	20.63	46	8956	19916	53320148
Toxic epidermal necrolysis	70.72	20.63	46	8956	23504	53316560
Rash maculo-papular	70.06	20.63	50	8952	29699	53310365
Eosinophilia	67.34	20.63	43	8959	21292	53318772
Acute generalised exanthematous pustulosis	63.06	20.63	32	8970	10249	53329815
Fatigue	60.55	20.63	24	8978	730482	52609582
Acinetobacter infection	58.99	20.63	18	8984	1485	53338579
Delirium	57.45	20.63	51	8951	41378	53298686
Pain	56.33	20.63	15	8987	588383	52751681
Product use in unapproved indication	52.94	20.63	79	8923	112210	53227854
Pseudomonas infection	51.28	20.63	28	8974	10400	53329664
Aplasia	50.94	20.63	21	8981	4171	53335893
Enterococcal infection	50.57	20.63	25	8977	7573	53332491
Agranulocytosis	49.31	20.63	37	8965	23712	53316352
Klebsiella infection	46.66	20.63	24	8978	7902	53332162
Headache	45.44	20.63	17	8985	536804	52803260
Eosinophilic pneumonia acute	44.31	20.63	11	8991	419	53339645
Hepatotoxicity	44.07	20.63	37	8965	27843	53312221
Central nervous system injury	43.43	20.63	9	8993	149	53339915
Respiratory failure	42.15	20.63	67	8935	100445	53239619
Acute respiratory distress syndrome	41.15	20.63	33	8969	23299	53316765
Tic	39.51	20.63	13	8989	1369	53338695
Thrombocytopenia	39.46	20.63	78	8924	138649	53201415
Mycobacterium abscessus infection	39.39	20.63	11	8991	664	53339400
Arthralgia	38.77	20.63	13	8989	439770	52900294
Pyrexia	38.62	20.63	152	8850	403041	52937023
Geotrichum infection	38.41	20.63	10	8992	462	53339602
Generalised tonic-clonic seizure	37.09	20.63	34	8968	28724	53311340
Fall	36.45	20.63	8	8994	358432	52981632
Dermatitis exfoliative	35.02	20.63	18	8984	5918	53334146
Muscle twitching	35.01	20.63	26	8976	16400	53323664
Splenic injury	34.47	20.63	8	8994	228	53339836
Liver injury	34.24	20.63	29	8973	22074	53317990
Hyperchloraemia	33.83	20.63	10	8992	740	53339324
Acute kidney injury	33.10	20.63	106	8896	253762	53086302
Clostridium difficile colitis	32.83	20.63	27	8975	19738	53320326
Hypochromasia	32.14	20.63	8	8994	308	53339756
Inflammatory marker increased	31.48	20.63	17	8985	6173	53333891
Aspergillus infection	31.08	20.63	18	8984	7478	53332586
Malaise	30.76	20.63	11	8991	357606	52982458
Toxic skin eruption	30.73	20.63	22	8980	13117	53326947
Hepatitis fulminant	30.47	20.63	14	8988	3605	53336459
Bone marrow failure	30.18	20.63	31	8971	30084	53309980
Renal failure	29.42	20.63	63	8939	118389	53221675
Bronchopulmonary aspergillosis	28.67	20.63	18	8984	8647	53331417
Granulomatous liver disease	28.61	20.63	9	8993	821	53339243
Clostridium difficile infection	28.47	20.63	29	8973	27864	53312200
Granulomatosis with polyangiitis	27.46	20.63	11	8991	2028	53338036
Cross sensitivity reaction	27.22	20.63	11	8991	2076	53337988
Guillain-Barre syndrome	26.85	20.63	13	8989	3762	53336302
Anisocytosis	26.83	20.63	8	8994	610	53339454
Fungaemia	26.77	20.63	11	8991	2166	53337898
Disorganised speech	26.47	20.63	9	8993	1048	53339016
Systemic candida	26.29	20.63	12	8990	3045	53337019
Electrocardiogram QT prolonged	25.57	20.63	39	8963	56364	53283700
Ototoxicity	25.28	20.63	9	8993	1201	53338863
Disseminated intravascular coagulation	24.82	20.63	23	8979	19696	53320368
Dermatitis bullous	24.63	20.63	16	8986	8147	53331917
Type IV hypersensitivity reaction	24.52	20.63	11	8991	2681	53337383
Megacolon	24.40	20.63	10	8992	1956	53338108
Nocardiosis	24.29	20.63	10	8992	1977	53338087
Drug level below therapeutic	24.00	20.63	12	8990	3721	53336343
Nephropathy toxic	23.91	20.63	16	8986	8556	53331508
Drug eruption	23.65	20.63	25	8977	25069	53314995
Deafness	23.51	20.63	21	8981	17155	53322909
Pneumonia klebsiella	23.45	20.63	10	8992	2159	53337905
Hypersensitivity	22.86	20.63	4	8998	210661	53129403
Cholestasis	22.57	20.63	26	8976	28669	53311395
Pseudomembranous colitis	22.41	20.63	11	8991	3280	53336784
Nasopharyngitis	22.35	20.63	3	8999	192292	53147772
Abdominal discomfort	22.31	20.63	5	8997	221057	53119007
Back pain	22.28	20.63	6	8996	234241	53105823
Hepatic infarction	22.07	20.63	7	8995	656	53339408
Hepatic function abnormal	21.87	20.63	29	8973	36870	53303194
Moraxella infection	21.51	20.63	6	8996	361	53339703
Escherichia infection	21.15	20.63	17	8985	12033	53328031
Constipation	21.03	20.63	4	8998	198408	53141656
Pain in extremity	20.95	20.63	11	8991	285039	53055025

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Epilepsy	275.20	17.79	147	12911	21962	32478506
Pathogen resistance	250.50	17.79	106	12952	9404	32491064
Septic shock	156.04	17.79	164	12894	68825	32431643
Drug resistance	150.28	17.79	101	12957	22864	32477604
Multiple organ dysfunction syndrome	145.54	17.79	159	12899	69695	32430773
Eosinophilia	113.43	17.79	88	12970	24870	32475598
Toxic epidermal necrolysis	105.49	17.79	78	12980	20515	32479953
Rash maculo-papular	92.30	17.79	82	12976	27940	32472528
Thrombocytopenia	88.30	17.79	188	12870	148111	32352357
Drug ineffective	83.00	17.79	338	12720	383139	32117329
Toxic skin eruption	80.56	17.79	53	13005	11561	32488907
Product use in unapproved indication	79.86	17.79	133	12925	87071	32413397
Drug reaction with eosinophilia and systemic symptoms	78.30	17.79	80	12978	32405	32468063
Seizure	75.30	17.79	143	12915	103711	32396757
Ototoxicity	74.40	17.79	27	13031	1585	32498883
Fatigue	68.11	17.79	28	13030	350673	32149795
Nocardiosis	64.45	17.79	31	13027	3700	32496768
Pseudomonas infection	60.23	17.79	45	13013	12011	32488457
Sepsis	55.99	17.79	165	12893	158669	32341799
Respiratory failure	54.81	17.79	128	12930	107054	32393414
Klebsiella infection	54.19	17.79	36	13022	7976	32492492
Hepatic cytolysis	52.91	17.79	36	13022	8297	32492171
Deafness neurosensory	51.03	17.79	24	13034	2724	32497744
Graft versus host disease	51.02	17.79	39	13019	10767	32489701
Mycobacterium abscessus infection	50.61	17.79	16	13042	614	32499854
Fungaemia	49.71	17.79	23	13035	2516	32497952
Fall	48.34	17.79	10	13048	196191	32304277
Electrocardiogram QT prolonged	45.31	17.79	67	12991	39574	32460894
Candida infection	45.30	17.79	44	13014	16759	32483709
Acute respiratory distress syndrome	44.85	17.79	53	13005	25200	32475268
Disseminated intravascular coagulation	41.76	17.79	49	13009	23127	32477341
Pain	41.44	17.79	12	13046	187544	32312924
Delirium	41.35	17.79	68	12990	43978	32456490
Bronchopulmonary aspergillosis	41.01	17.79	38	13020	13649	32486819
Disorganised speech	40.43	17.79	14	13044	716	32499752
Generalised tonic-clonic seizure	39.47	17.79	45	13013	20594	32479874
Agranulocytosis	37.98	17.79	47	13011	23430	32477038
Dizziness	37.07	17.79	19	13039	209599	32290869
Geotrichum infection	36.71	17.79	12	13046	513	32499955
Venoocclusive disease	36.20	17.79	19	13039	2727	32497741
Brain abscess	35.02	17.79	19	13039	2915	32497553
Headache	34.36	17.79	18	13040	196179	32304289
Pseudomembranous colitis	34.20	17.79	19	13039	3053	32497415
Arthralgia	33.70	17.79	9	13049	148439	32352029
Dysphoria	33.37	17.79	17	13041	2294	32498174
Botulism	33.12	17.79	9	13049	201	32500267
Enterococcal infection	32.57	17.79	28	13030	9119	32491349
Pancytopenia	32.28	17.79	95	12963	91140	32409328
Vascular pseudoaneurysm thrombosis	31.75	17.79	7	13051	62	32500406
Treatment failure	30.90	17.79	56	13002	39107	32461361
Clostridium difficile colitis	30.41	17.79	33	13025	14298	32486170
Muscle twitching	29.48	17.79	26	13032	8758	32491710
Incision site pain	29.46	17.79	15	13043	2022	32498446
Cardiac valve vegetation	28.64	17.79	10	13048	524	32499944
Pyrexia	28.21	17.79	222	12836	319746	32180722
Clostridium test positive	27.64	17.79	15	13043	2302	32498166
Tuberculosis	27.64	17.79	25	13033	8704	32491764
Enterococcus test positive	27.01	17.79	11	13047	883	32499585
Completed suicide	26.65	17.79	3	13055	92514	32407954
Back pain	26.62	17.79	6	13052	111047	32389421
Hypoalbuminaemia	26.46	17.79	28	13030	11794	32488674
Condition aggravated	26.41	17.79	128	12930	155533	32344935
Hepatotoxicity	25.49	17.79	35	13023	19302	32481166
Fungal test positive	24.98	17.79	9	13049	517	32499951
Hepatitis cholestatic	24.95	17.79	23	13035	8202	32492266
Splenic candidiasis	24.91	17.79	6	13052	81	32500387
Status epilepticus	24.35	17.79	27	13031	11979	32488489
Asthenia	24.05	17.79	36	13022	235908	32264560
Syncope	23.43	17.79	4	13054	90120	32410348
Mental disorder	23.32	17.79	29	13029	14519	32485949
Leukocytosis	23.05	17.79	37	13021	23430	32477038
Functional gastrointestinal disorder	22.59	17.79	13	13045	2233	32498235
Rash erythematous	22.51	17.79	37	13021	23902	32476566
Partial seizures	21.86	17.79	16	13042	4134	32496334
Acoustic neuroma	21.71	17.79	6	13052	143	32500325
Escherichia infection	21.68	17.79	20	13038	7140	32493328
Mucormycosis	21.55	17.79	18	13040	5636	32494832
Neurological symptom	21.41	17.79	15	13043	3620	32496848
Hyperlactacidaemia	21.24	17.79	14	13044	3060	32497408
Dehydration	20.88	17.79	13	13045	128945	32371523
Tic	20.74	17.79	12	13046	2082	32498386
Dermatitis exfoliative generalised	20.33	17.79	14	13044	3287	32497181
Toxicity to various agents	20.32	17.79	25	13033	178016	32322452
Cerebrovascular accident	20.02	17.79	5	13053	86315	32414153
Gait disturbance	19.97	17.79	4	13054	80404	32420064
Drug eruption	19.90	17.79	31	13027	19135	32481333
Myocardial infarction	19.89	17.79	13	13045	125663	32374805
Megacolon	19.68	17.79	11	13047	1787	32498681
Pneumonia klebsiella	19.59	17.79	13	13045	2872	32497596
Pulmonary physical examination abnormal	19.37	17.79	4	13054	25	32500443
Liver injury	19.35	17.79	26	13032	14048	32486420
Psychiatric symptom	19.26	17.79	14	13044	3580	32496888
Immunosuppressant drug level increased	18.82	17.79	16	13042	5129	32495339
Haemophagocytic lymphohistiocytosis	18.82	17.79	23	13035	11312	32489156
Constipation	18.78	17.79	14	13044	126359	32374109
Osmotic demyelination syndrome	18.56	17.79	8	13050	740	32499728
Antimicrobial susceptibility test resistant	18.41	17.79	6	13052	254	32500214
Acinetobacter test positive	17.98	17.79	5	13053	122	32500346
Peripheral swelling	17.83	17.79	3	13055	68342	32432126

Pharmacologic Action:

Source	Code	Description
ATC	J01DH51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
ATC	J01DH56	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs	indication	11218009
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Streptococcus	indication	34020007
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Haemophilus influenzae pneumonia	indication	70036007
Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs	indication	71057007
Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs	indication	71120004
Abdominal abscess	indication	75100008
Endometritis	indication	78623009	DOID:1002
Infection of bone	indication	111253001
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Bacterial endocarditis	indication	301183007
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs	indication	406574007
Acute exacerbation of chronic bronchitis	indication	425748003
Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs	indication	840588006
Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs	indication	1137353009
Gram-Negative Aerobic Bacillary Pneumonia	indication
Enterobacter Pneumonia	indication
Diabetic Foot Infection	indication
Inflammatory Disease of Female Pelvic Organs	indication
Pyrexia of unknown origin	off-label use	7520000
Inhalational anthrax	off-label use	11389007
Cutaneous anthrax	off-label use	84980006	DOID:7426
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Infection by Campylobacter fetus	off-label use	111835002
Gas gangrene caused by clostridium perfringens	off-label use	266093005
Anthrax	off-label use	409498004	DOID:7427
Melioidosis	off-label use	428111003	DOID:5052
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Clostridium Perfringens Empyema	off-label use
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Lesion of brain	contraindication	301766008
Pseudomembranous enterocolitis	contraindication	397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.9	acidic
pKa2	9.92	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	Nov. 19, 2029	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	Nov. 19, 2029	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	Nov. 19, 2029	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	July 16, 2024	NEW CHEMICAL ENTITY
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	July 16, 2029	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme	PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 4	Enzyme	Q5D1E9_STAAU		IC50	7.30	WOMBAT-PK
Penicillin-binding protein 1	Enzyme	A1KS91_NEIMF		IC50	7	WOMBAT-PK
Beta-lactamase	Enzyme	A2RP81_CITFR		Ki	7.22	CHEMBL
Beta-lactamase GES-13	Enzyme	D1MIX9_PSEAI		IC50	6.82	CHEMBL

External reference:

ID	Source
4017969	VUID
N0000146319	NUI
D00206	KEGG_DRUG
4017969	VANDF
C0020933	UMLSCUI
CHEBI:51799	CHEBI
ID1	PDB_CHEM_ID
CHEMBL43708	ChEMBL_ID
CHEMBL148	ChEMBL_ID
DB01598	DRUGBANK_ID
D015378	MESH_DESCRIPTOR_UI
104838	PUBCHEM_CID
10821	IUPHAR_LIGAND_ID
74431-23-5	SECONDARY_CAS_RN
71OTZ9ZE0A	UNII
5690	RXNORM
4869	MMSL
d04401	MMSL
002813	NDDF
424285002	SNOMEDCT_US
46558003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3514	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3516	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3551	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3552	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections